Concordant and discordant pairs for EBNA1 and ANO2 seropositivity in samples collected <15 years before clinical onset
| Matched controls | ||||||
| EBNA1−, ANO2- | EBNA1−, ANO2+ | EBNA1+, ANO2− | EBNA1+, ANO2+ | Total | ||
| Pre-MS | EBNA1−, ANO2- | 9 | 0 | 24 | 2 | 35 |
| EBNA1−, ANO2+ | 0 | 0 | 1 | 0 | 1 | |
| EBNA1+, ANO2− | 39 | 0 | 387 | 29 | 431 | |
| EBNA1+, ANO2+ | 7 | 0 | 58 | 1 | 91 | |
| Total | 55 | 0 | 449 | 54 | 558 | |
Concordant (grey shading) and discordant matched pairs for EBNA1 and ANO2 seropositivity and seronegativity. Showing that in the last 15-year period before clinical MS onset there are more EBNA1 seropositive samples with also seropositive ANO2 in the pre-MS group (n=58) than in the control group (n=29, p=0.002). There are also more EBNA1 seropositive samples in the ANO2 seronegative pre-MS group (n=39) than in ANO2 seronegative control group (n=24, p=0.038). Numbers used in comparisons in bold. P values from McNemar test.
ANO2, anoctamin 2; EBNA1, Epstein-Barr virus nuclear antigen 1; MS, multiple sclerosis.